MedTrace Logo

AZD6423 SAD/MAD Study in Healthy Volunteers

NCT01926366 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2014-04-04

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled study of single and multiple ascending dosage levels of AZD6423 in healthy volunteers. The study includes an up to 28-day screening period, an in-house period during which AZD6423 or placebo will be administered IV, and a 4- to 10-day follow-up period after discharge.

Conditions

  • Healthy Volunteers.

Interventions

DRUG

AZD6423

Drug: AZD6423 Single or Multiple doses via infusion.

DRUG

Placebo

Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion

Sponsors & Collaborators

Principal Investigators

  • David Han, M.D. · California Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01926366 on ClinicalTrials.gov